<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: There is increasing interest in <z:chebi fb="0" ids="17230">homocysteine</z:chebi> as a risk factor for neuropsychiatric disorders such as <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:hpo ids='HP_0000726'>dementia</z:hpo>, <z:hpo ids='HP_0000716'>depression</z:hpo> and <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This article reviews the current literature on the relationship between <z:chebi fb="0" ids="17230">homocysteine</z:chebi> and these disorders to ascertain if any clinical recommendations can be made </plain></SENT>
<SENT sid="2" pm="."><plain>METHOD: A MEDLINE and EMBASE search was made for English language publications between 1966 and 2002 using the search terms '<z:chebi fb="0" ids="17230">Homocysteine</z:chebi>' and '<z:hpo ids='HP_0001297'>Stroke</z:hpo>', '<z:hpo ids='HP_0000726'>Dementia</z:hpo>', 'Vascular <z:hpo ids='HP_0000726'>Dementia</z:hpo>', 'Alzheimer's <z:hpo ids='HP_0000726'>dementia</z:hpo>', '<z:e sem="disease" ids="C0009241" disease_type="Mental or Behavioral Dysfunction" abbrv="">Cognition disorders</z:e> or <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> or <z:e sem="disease" ids="C0025261" disease_type="Mental or Behavioral Dysfunction" abbrv="">memory disorders</z:e>', '<z:hpo ids='HP_0000716'>Depression</z:hpo> or <z:e sem="disease" ids="C0868892,C0868894,C0011581,C0012706,C0868893" disease_type="Mental or Behavioral Dysfunction" abbrv="">depressive disorders</z:e>' or '<z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e>' </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, individual articles were hand searched for relevant references </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Cross-sectional studies consistently suggest that elevated <z:chebi fb="0" ids="17230">homocysteine</z:chebi> increases the risk of <z:hpo ids='HP_0001297'>stroke</z:hpo>, and may also increase the risk of leukoariosis, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD), <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> and <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) </plain></SENT>
<SENT sid="5" pm="."><plain>Longitudinal studies of <z:chebi fb="0" ids="17230">homocysteine</z:chebi> as a risk factor are few and inconsistently supportive of these associations </plain></SENT>
<SENT sid="6" pm="."><plain>No intervention trials to determine the effect of lowering <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels have yet been published </plain></SENT>
<SENT sid="7" pm="."><plain>The pathological mechanisms for <z:chebi fb="0" ids="17230">homocysteine</z:chebi>-mediated disease await complete elucidation </plain></SENT>
<SENT sid="8" pm="."><plain>Mild <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> is common in the elderly population, and <z:chebi fb="3" ids="37445">folate</z:chebi> supplementation can decrease <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The epidemiological evidence for <z:chebi fb="0" ids="17230">homocysteine</z:chebi> as a risk factor for neuropsychiatric disease is an emerging area of great interest </plain></SENT>
<SENT sid="10" pm="."><plain>Screening the population for <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> cannot be recommended at this stage, but individuals at increased risk of cerebrovascular disease or <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> should be investigated and treated for elevated <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels </plain></SENT>
</text></document>